Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer
Conditions
Cervical Cancer - Endometrial Cancer - Gastrointestinal Complications - Perioperative/Postoperative Complications - Radiation Toxicity - Urinary Complications - Urinary Tract Toxicity
Conditions: official terms
Postoperative Complications - Radiation Injuries - Uterine Cervical Neoplasms
Conditions: Keywords
gastrointestinal complications, perioperative/postoperative complications, radiation toxicity, urinary complications, urinary tract toxicity, endometrial clear cell carcinoma, endometrial papillary serous carcinoma, stage IA endometrial carcinoma, stage IB endometrial carcinoma, stage II endometrial carcinoma, stage IIIA endometrial carcinoma, stage IIIB endometrial carcinoma, stage IIIC endometrial carcinoma, endometrial adenocarcinoma, cervical adenocarcinoma, stage IB cervical cancer, stage IIA cervical cancer, stage IIB cervical cancer
Study Type
Interventional
Study Phase
Phase 3
Study Design
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: 3-dimensional conformal radiation therapy Type: Radiation
Name: intensity-modulated radiation therapy Type: Radiation
Overall Status
Recruiting
Summary
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: This randomized phase III trial is studying two different methods of radiation and their side effects and comparing how well they work in treating endometrial and cervical cancer after surgery.
Detailed Description
OBJECTIVES:

Primary

- To determine if pelvic intensity-modulated radiation therapy (IMRT) reduces acute gastrointestinal toxicity in the 5th week (after 23-25 fractions) of pelvic radiation as measured with the expanded prostate cancer index composite (EPIC) instrument.

Secondary

- To determine if grade 2+ gastrointestinal toxicity (Common Terminology Criteria for Adverse Events version 4.0 [CTCAE v. 4.0]) is reduced with IMRT compared to conventional whole-pelvis radiation therapy (WPRT).

- To determine if grade 2+ hematologic toxicity (CTCAE v. 4.0) is reduced with IMRT compared to conventional WPRT.

- To determine if urinary toxicity is reduced with IMRT using the EPIC urinary domain.

- To validate EPIC bowel and urinary domains in women undergoing either IMRT pelvic radiation treatment or four-field pelvic radiation treatment for endometrial or cervical cancer.

- To assess the impact of pelvic IMRT on quality of life using the Functional Assessment of Cancer Therapy-General (FACT-G) with cervix subscale.

- To determine if there is any difference in local-regional control, disease-free survival, and overall survival between patients treated with IMRT as compared to conventional WPRT.

- To perform a health-utilities analysis to measure the financial impact of pelvic IMRT via the EQ-5D instrument.

- To identify molecular predictors of radiation toxicity and novel circulating cancer biomarkers.

OUTLINE: This is a multicenter study. Patients are stratified according to type of cancer (endometrial vs cervical), chemotherapy (none vs 5 courses of weekly cisplatin at 40 mg/m²), and radiation dose (45 Gy vs 50.4 Gy). Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients undergo standard (3-dimensional) radiation therapy 5 days a week for up to 5-6 weeks.

- Arm II: Patients undergo intensity-modulated radiation therapy (IMRT) 5 days a week for up to 5-6 weeks.

Some patients receive cisplatin IV over 1 hour on day 1. Treatment continues weekly for 5 weeks, concurrently with radiation therapy, in the absence of unacceptable toxicity or disease progression.

Tissue and blood samples may be collected for biomarker and correlative analysis.

Quality of life may be assessed by questionnaires (including the Expanded Prostate Cancer Index Composite [EPIC], the Functional Assessment of Cancer Therapy-General [FACT-G, Version 4], the EQ-5D, and the Common Toxicity Criteria Adverse Events - Patient-Reported Outcome [PRO-CTCAE]) instruments at baseline and periodically during and after study therapy.

After completion of study therapy, patients are followed every 6 months for the first 2 years and then annually for 5 years.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Female
Criteria: DISEASE CHARACTERISTICS:

- Pathologically proven diagnosis of endometrial or cervical cancer

- Patients must have undergone a hysterectomy (total abdominal hysterectomy, vaginal hysterectomy or radical hysterectomy, or total laparoscopic hysterectomy) for carcinoma of the cervix or endometrium within 49 days prior to registration

- Performance of a bilateral salpingo-oophorectomy will be at the treating surgeon's discretion

- No positive or close (< 3 mm) resection margins

- Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:

- History/physical examination within 45 days prior to registration

- Computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT including the abdomen and pelvis should be performed for initial radiological staging (performed pre- or post-surgery within 90 days prior to registration)

- Imaging performed postoperatively should show no evidence of residual disease

- Any evidence of malignancy identified on preoperative imaging should have been completely resected surgically prior to protocol treatment

- Chest x-ray or chest CT must be performed within 90 days prior to registration (unless a PET-CT has been performed)

- Endometrial cancer:

- Patients with the following histologic features are eligible for pelvic radiation therapy without weekly cisplatin:

- Less than 50% myometrial invasion, grade 3 adenocarcinoma without uterine serous carcinoma (USC), or clear cell histology

- At least 50% myometrial invasion, grade 1-2 adenocarcinoma without USC, or clear cell histology

- Patients with the following histologic features may be treated with pelvic radiation with or without weekly cisplatin (the decision to add weekly cisplatin for these patients is at the treating physician's discretion):

- At least 50% myometrial invasion, grade 3 including USC and clear cell carcinoma

- International Federation of Gynecology and Obstetrics (FIGO) 2009 stage II endometrial cancer of any grade including USC and clear cell carcinoma

- FIGO 2009 stage IIIC1 (pelvic lymph node positive only, para-aortic nodes negative if removed) including USC and clear cell carcinoma. NOTE: If para-aortic nodes are not removed, CT abdomen or PET must demonstrate no evidence of lymphadenopathy.

- Cervical cancer:

- Patients with the following pathology findings may be treated with pelvic radiation with or without weekly cisplatin at the treating physician's discretion:

- Patients with intermediate-risk features including two of the following histologic findings after radical hysterectomy: 1/3 or more stromal invasion, lymph-vascular space invasion or large clinical tumor diameter (> 4 cm)

- Patients with cervical cancer treated with a simple hysterectomy with negative margins

- Patients with any of the following criteria following radical hysterectomy are eligible for this study and must receive weekly cisplatin:

- Positive resected pelvic nodes and para-aortic nodes negative if removed. NOTE: If para-aortic nodes are not removed, CT abdomen or PET CT must demonstrate no evidence of lymphadenopathy.

- Microscopic parametrial invasion with negative margins

- No patients with para-aortic nodal disease or who require extended-field radiotherapy beyond the pelvis

- No patients with histology consisting of endometrial stromal sarcoma, leiomyosarcoma, malignant mixed mullerian tumor (MMMT), or carcinosarcoma

- No evidence of metastatic disease outside of the pelvis

PATIENT CHARACTERISTICS:

- Zubrod performance status 0-2

- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm³

- Platelets ≥ 100,000 cells/mm³

- Hemoglobin (Hgb) ≥ 8.0 g/dL (the use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable)

- For patients receiving chemotherapy:

- Within 14 days prior to registration, serum creatinine ≤ 1.5 mg/dL AND calculated creatinine clearance ≥ 50 mL/min

- Aspartate aminotransferase (AST) ≤ 2 times upper limit of normal (ULN)

- Bilirubin ≤ 2 times ULN

- Alkaline phosphatase, magnesium, blood urea nitrogen (BUN), and electrolytes must be obtained and recorded

- Fertile patients must use effective contraception

- Not pregnant and/or breastfeeding

- Willing and able to complete the bowel and urinary domains of the expanded prostate cancer index composite (EPIC) instrument prior to registration

- No patients who exceed the weight/size limits of the treatment table or CT scanner

- No mental status changes or bladder control problems that make the patient unable to comply with bladder-filling instructions

- No prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 3 years

- No patients with active inflammatory bowel disease

- No severe, active co-morbidity, defined as follows:

- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months

- Transmural myocardial infarction within the last 6 months

- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration

- Other major medical illness that requires hospitalization or precludes study therapy at the time of registration

- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects (however, laboratory test coagulation parameters are not required for entry into this protocol)

- Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition (however, human immunodeficiency virus [HIV] testing is not required for entry into this protocol)

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior radiation therapy to the pelvis

- No prior treatment with platinum-based chemotherapy

- Patients may NOT receive amifostine or other protective reagents
Locations
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Status: Recruiting
Contact: Emily J. Grade - 602-747-9738
Arizona Oncology-Deer Valley Center
Phoenix, Arizona, United States
Status: Recruiting
Contact: David G. Brachman - 800-360-6371
Arizona Oncology Services Foundation
Scottsdale, Arizona, United States
Status: Recruiting
Contact: David G. Brachman - 800-360-6371
California Cancer Center - North Fresno
Fresno, California, United States
Status: Recruiting
Contact: Uma G. Swamy - 559-447-4050
UC San Diego Moores Cancer Center
La Jolla, California, United States
Status: Active, not recruiting
Kaiser Permanente Oakland-Broadway
Oakland, California, United States
Status: Recruiting
Contact: Samantha A. Seaward - 626-564-3455
Saint Joseph Hospital - Orange
Orange, California, United States
Status: Recruiting
Contact: Venita L. Williams - 714-734-6220
Feather River Cancer Center
Paradise, California, United States
Status: Recruiting
Contact: Sam Mazj - 530-876-7995 - haleew@ah.org
Pomona Valley Hospital Medical Center
Pomona, California, United States
Status: Recruiting
Contact: Yallapragada S. Rao - 909-865-9555
Kaiser Permanente-Rancho Cordova Cancer Center
Rancho Cardova, California, United States
Status: Recruiting
Contact: Samantha A. Seaward - 626-564-3455
Rohnert Park Cancer Center
Rohnert Park, California, United States
Status: Recruiting
Contact: Samantha A. Seaward - 626-564-3455
The Permanente Medical Group-Roseville Radiation Oncology
Roseville, California, United States
Status: Recruiting
Contact: Samantha A. Seaward - 626-564-3455
South Sacramento Cancer Center
Sacramento, California, United States
Status: Recruiting
Contact: Samantha A. Seaward - 626-564-3455
University of California at Davis Cancer Center
Sacramento, California, United States
Status: Recruiting
Contact: Jyoti S. Mayadev - 916-734-3089
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California, United States
Status: Recruiting
Contact: Samantha A. Seaward - 626-564-3455
Kaiser Permanente Cancer Treatment Center
South San Francisco, California, United States
Status: Recruiting
Contact: Samantha A. Seaward - 626-564-3455
University of Colorado Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado, United States
Status: Active, not recruiting
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, United States
Status: Recruiting
Contact: Keren Sturtz - 888-785-6789
Porter Adventist Hospital
Denver, Colorado, United States
Status: Recruiting
Contact: Keren Sturtz - 888-785-6789
Swedish Medical Center
Englewood, Colorado, United States
Status: Recruiting
Contact: Keren Sturtz - 888-785-6789
Rocky Mountain Cancer Centers-Littleton
Littleton, Colorado, United States
Status: Recruiting
Contact: Keren Sturtz - 888-785-6789
Longmont United Hospital
Longmont, Colorado, United States
Status: Recruiting
Contact: Keren Sturtz - 888-785-6789
McKee Medical Center
Loveland, Colorado, United States
Status: Recruiting
Contact: Keren Sturtz - 888-785-6789
Christiana Care Health System-Christiana Hospital
Newark, Delaware, United States
Status: Recruiting
Contact: Adam Raben - 302-733-6227
Beebe Health Campus
Rehoboth Beach, Delaware, United States
Status: Recruiting
Contact: Adam Raben - 302-733-6227
Washington Hospital Center
Washington, District of Columbia, United States
Status: Recruiting
Contact: Adedamola (Mola) B. Omogbehin - 202-877-8839
University of Florida
Gainesville, Florida, United States
Status: Recruiting
Contact: Anamaria R. Yeung - 352-273-8675 - trials@cancer.ufl.edu
University of Florida Health Science Center
Jacksonville, Florida, United States
Status: Recruiting
Contact: Anamaria R. Yeung - 352-273-8675 - trials@cancer.ufl.edu
Jackson Memorial Hospital-Holtz Children's Hospital
Miami, Florida, United States
Status: Recruiting
Contact: Lorraine Portelance - 866-574-5124 - Sylvester@emergingmed.com
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
Status: Recruiting
Contact: Lorraine Portelance - 866-574-5124 - Sylvester@emergingmed.com
Emory University/Winship Cancer Institute
Atlanta, Georgia, United States
Status: Recruiting
Contact: Joseph W. Shelton - 404-489-9164
Grady Health System
Atlanta, Georgia, United States
Status: Recruiting
Contact: Joseph W. Shelton - 404-489-9164
Northside Hospital
Atlanta, Georgia, United States
Status: Recruiting
Contact: Sahar E. Rosenbaum - 404-303-3355
Piedmont Hospital
Atlanta, Georgia, United States
Status: Recruiting
Contact: Adam W. Nowlan - 404-425-7943 - ORS@piedmont.org
Northside Hospital-Forsyth
Cumming, Georgia, United States
Status: Recruiting
Contact: Sahar E. Rosenbaum - 404-303-3355
Northeast Georgia Medical Center
Gainesville, Georgia, United States
Status: Recruiting
Contact: Frank G. Lake - 770-219-8800 - cancerpatient.navigator@nghs.com
Saint Joseph's-Candler Health System
Savannah, Georgia, United States
Status: Recruiting
Contact: John A. Pablo - 912-819-5704
Leeward Radiation Oncology Center
Ewa Beach, Hawaii, United States
Status: Recruiting
Contact: Paul A. DeMare - 808-545-8548
Queen's Medical Center
Honolulu, Hawaii, United States
Status: Recruiting
Contact: Paul A. DeMare - 808-545-8548
The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii, United States
Status: Recruiting
Contact: Paul A. DeMare - 808-545-8548
University of Hawaii
Honolulu, Hawaii, United States
Status: Recruiting
Contact: Paul A. DeMare - 808-545-8548
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States
Status: Recruiting
Contact: Samir Narayan - 734-712-4673
Advocate Illinois Masonic Medical Center
Chicago, Illinois, United States
Status: Recruiting
Contact: Paige L. Dorn - 773-296-5360
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, United States
Status: Recruiting
Contact: Anu Thakrar - 312-864-6000
Northwestern University
Chicago, Illinois, United States
Status: Recruiting
Contact: Eric D. Donnelly - 312-695-1301 - cancer@northwestern.edu
University of Illinois
Chicago, Illinois, United States
Status: Active, not recruiting
Ingalls Memorial Hospital
Harvey, Illinois, United States
Status: Recruiting
Contact: Sulochana D. Yalavarthi - 708-915-4673 - clinicaltrials@ingalls.org
Saint Vincent Anderson Regional Hospital/Cancer Center
Anderson, Indiana, United States
Status: Recruiting
Contact: Maria J. Valente - 904-538-3667
Franciscan Saint Margaret Health-Dyer Campus
Dyer, Indiana, United States
Status: Recruiting
Contact: Robert D. Prock - 708-891-9305
Radiation Oncology Associates PC
Fort Wayne, Indiana, United States
Status: Recruiting
Contact: Brian K. Chang - 260-373-8888 - parkviewresearch@parkview.com
Franciscan Saint Margaret Health-Hammond Campus
Hammond, Indiana, United States
Status: Recruiting
Contact: Robert D. Prock - 708-891-9305
McFarland Clinic PC-William R Bliss Cancer Center
Ames, Iowa, United States
Status: Recruiting
Contact: Joseph J. Merchant - 515-239-2621
Mercy Cancer Center-West Lakes
Clive, Iowa, United States
Status: Recruiting
Contact: Robert J. Behrens - 888-244-6061 - sherrijr@iora.org
Iowa Methodist Medical Center
Des Moines, Iowa, United States
Status: Recruiting
Contact: Robert J. Behrens - 888-244-6061 - sherrijr@iora.org
Mercy Medical Center - Des Moines
Des Moines, Iowa, United States
Status: Recruiting
Contact: Robert J. Behrens - 888-244-6061 - sherrijr@iora.org
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States
Status: Recruiting
Contact: Robert W. Veith - 504-568-2428 - emede1@lsuhsc.edu
Ochsner Clinic CCOP
New Orleans, Louisiana, United States
Status: Withdrawn
Ochsner Medical Center Jefferson
New Orleans, Louisiana, United States
Status: Recruiting
Contact: Mini J. Elnaggar - 888-562-4763
Greater Baltimore Medical Center
Baltimore, Maryland, United States
Status: Recruiting
Contact: Geoffrey A. Neuner - 443-849-3706
Sinai Hospital of Baltimore
Baltimore, Maryland, United States
Status: Active, not recruiting
Peninsula Regional Medical Center
Salisbury, Maryland, United States
Status: Recruiting
Contact: Matthew L. Snyder - 866-922-6237
Holy Cross Hospital
Silver Spring, Maryland, United States
Status: Recruiting
Contact: Sheela D. Modin - 310-754-7552
Boston Medical Center
Boston, Massachusetts, United States
Status: Recruiting
Contact: Lisa A. Kachnic - 617-638-8265
Brigham and Women's Hospital
Boston, Massachusetts, United States
Status: Recruiting
Contact: Akila N. Viswanathan - 617-724-5200
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Status: Recruiting
Contact: Akila N. Viswanathan - 617-724-5200
Lowell General Hospital
Lowell, Massachusetts, United States
Status: Recruiting
Contact: Akila N. Viswanathan - 617-724-5200
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional
Milford, Massachusetts, United States
Status: Recruiting
Contact: Akila N. Viswanathan - 617-724-5200
Dana-Farber/Brigham and Women's Cancer Center at South Shore
South Weymouth, Massachusetts, United States
Status: Recruiting
Contact: Akila N. Viswanathan - 617-724-5200
D'Amour Center for Cancer Care
Springfield, Massachusetts, United States
Status: Recruiting
Contact: Seth A. Kaufman - 413-794-9338
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, United States
Status: Recruiting
Contact: Samir Narayan - 734-712-4673
Saint John Hospital and Medical Center
Detroit, Michigan, United States
Status: Recruiting
Contact: Samir Narayan - 734-712-4673
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
Status: Active, not recruiting
Mercy Health Saint Mary's
Grand Rapids, Michigan, United States
Status: Recruiting
Contact: Gilbert D. Padula - 616-685-5225
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, United States
Status: Recruiting
Contact: Gilbert D. Padula - 616-685-5225
Saint John Macomb-Oakland Hospital
Warren, Michigan, United States
Status: Recruiting
Contact: Samir Narayan - 734-712-4673
Sanford Clinic North-Bemidgi
Bemidji, Minnesota, United States
Status: Recruiting
Contact: Preston D. Steen - 701-234-6161
United Hospital
Saint Paul, Minnesota, United States
Status: Recruiting
Contact: Paul W. Sperduto - 952-993-1517 - MMCCOP@parknicollet.com
Ridgeview Medical Center
Waconia, Minnesota, United States
Status: Recruiting
Contact: Paul W. Sperduto - 952-993-1517 - MMCCOP@parknicollet.com
Saint John's Mercy Medical Center
Saint Louis, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532 - sherrijr@iora.org
CoxHealth South Hospital
Springfield, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532 - sherrijr@iora.org
Mercy Hospital Springfield
Springfield, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532 - sherrijr@iora.org
Billings Clinic
Billings, Montana, United States
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
The Nebraska Medical Center
Omaha, Nebraska, United States
Status: Recruiting
Contact: Andrew O. Wahl - 800-999-5465
Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County
Mount Holly, New Jersey, United States
Status: Recruiting
Contact: Lemuel S. Ariaratnam - 888-847-8823
Capital Health Medical Center-Hopewell
Pennington, New Jersey, United States
Status: Recruiting
Contact: Shirnett K. Williamson - 800-255-3440
Virtua West Jersey Hospital Voorhees
Voorhees, New Jersey, United States
Status: Recruiting
Contact: Lemuel S. Ariaratnam - 888-847-8823
University of New Mexico
Albuquerque, New Mexico, United States
Status: Recruiting
Contact: Thomas M. Schroeder - 505-272-6972
Long Island Jewish Medical Center
New Hyde Park, New York, United States
Status: Recruiting
Contact: Beatrice F. Bloom - 516-734-8900
North Shore-LIJ Health System/Center for Advanced Medicine
New Hyde Park, New York, United States
Status: Recruiting
Contact: Beatrice F. Bloom - 516-734-8900
Stony Brook University Medical Center
Stony Brook, New York, United States
Status: Recruiting
Contact: Tamara E. Weiss - 800-862-2215
South Atlantic Radiation Oncology
Supply, North Carolina, United States
Status: Recruiting
Contact: Michael A. Papagikos - 910-251-1839
Coastal Carolina Radiation Oncology
Wilmington, North Carolina, United States
Status: Recruiting
Contact: Michael A. Papagikos - 910-251-1839
New Hanover Regional Medical Center
Wilmington, North Carolina, United States
Status: Recruiting
Contact: Michael A. Papagikos - 910-251-1839
Sanford Bismarck Medical Center
Bismarck, North Dakota, United States
Status: Recruiting
Contact: Preston D. Steen - 701-234-6161
Summa Akron City Hospital/Cooper Cancer Center
Akron, Ohio, United States
Status: Recruiting
Contact: Charles A. Kunos - 330-375-6101
Summa Barberton Hospital
Barberton, Ohio, United States
Status: Recruiting
Contact: Charles A. Kunos - 330-375-6101
Geaugra Hospital
Chardon, Ohio, United States
Status: Recruiting
Contact: Rodney J. Ellis - 800-641-2422
Case Western Reserve University
Cleveland, Ohio, United States
Status: Recruiting
Contact: Tracy Sherertz - 800-641-2422
The Mark H Zangmeister Center
Columbus, Ohio, United States
Status: Recruiting
Contact: John P. Kuebler - 800-446-5532
Summa Health Center at Lake Medina
Medina, Ohio, United States
Status: Recruiting
Contact: Charles A. Kunos - 330-375-6101
Lake University Ireland Cancer Center
Mentor, Ohio, United States
Status: Recruiting
Contact: Rodney J. Ellis - 800-641-2422
Southwest General Health Center Ireland Cancer Center
Middleburg Heights, Ohio, United States
Status: Recruiting
Contact: Rodney J. Ellis - 800-641-2422
UHHS-Chagrin Highlands Medical Center
Orange Village, Ohio, United States
Status: Recruiting
Contact: Rodney J. Ellis - 800-641-2422
Southern Ohio Medical Center
Portsmouth, Ohio, United States
Status: Recruiting
Contact: John P. Kuebler - 800-446-5532
UHHS-Westlake Medical Center
Westlake, Ohio, United States
Status: Recruiting
Contact: Rodney J. Ellis - 800-641-2422
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Status: Recruiting
Contact: Terence S. Herman - 405-271-4272 - julie-traylor@ouhsc.edu
Abington Memorial Hospital
Abington, Pennsylvania, United States
Status: Active, not recruiting
Paoli Memorial Hospital
Paoli, Pennsylvania, United States
Status: Recruiting
Contact: Albert S. DeNittis - 866-225-5654
Radiation Therapy Oncology Group
Philadelphia, Pennsylvania, United States
Status: Recruiting
Contact: Ann H. Klopp - aklopp@mdanderson.org
Mount Nittany Medical Center
State College, Pennsylvania, United States
Status: Recruiting
Contact: Jerome D. Derdel - 814-231-7813 - smoyer@mountnittany.org
Reading Hospital
West Reading, Pennsylvania, United States
Status: Recruiting
Contact: Albert Yuen - 610-988-9323
Lankenau Hospital
Wynnewood, Pennsylvania, United States
Status: Recruiting
Contact: Albert S. DeNittis - 866-225-5654
Medical University of South Carolina
Charleston, South Carolina, United States
Status: Recruiting
Contact: Samuel L. Cooper - 843-792-9321
Self Regional Healthcare
Greenwood, South Carolina, United States
Status: Recruiting
Contact: Samuel L. Cooper - 843-792-9321
Rapid City Regional Hospital
Rapid City, South Dakota, United States
Status: Recruiting
Contact: Michael J. Swartz - 605-716-3982 - research@rcrh.org
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, United States
Status: Recruiting
Contact: Miroslaw A. Mazurczak - 605-328-1367
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Status: Recruiting
Contact: Kevin V. Albuquerque - 214-648-7097
M D Anderson Cancer Center
Houston, Texas, United States
Status: Active, not recruiting
M D Anderson Cancer Center
Houston, Texas, United States
Status: Recruiting
Contact: Ann H. Klopp - 713-792-3245
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Status: Recruiting
Contact: Tony Y. Eng - 210-567-0653 - che@uthscsa.edu
Logan Regional Hospital
Logan, Utah, United States
Status: Recruiting
Contact: R. J. Lee - 801-507-3950
Intermountain Medical Center
Murray, Utah, United States
Status: Recruiting
Contact: R. J. Lee - 801-507-3950
Dixie Medical Center Regional Cancer Center
Saint George, Utah, United States
Status: Recruiting
Contact: R. J. Lee - 801-507-3950
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States
Status: Recruiting
Contact: David K. Gaffney - 801-581-4477 - clinical.trials@hci.utah.edu
LDS Hospital
Salt Lake City, Utah, United States
Status: Recruiting
Contact: R. J. Lee - 801-507-3950
Saint Francis Hospital
Federal Way, Washington, United States
Status: Recruiting
Contact: Huong T. Pham - 800-354-9527
Virginia Mason CCOP
Seattle, Washington, United States
Status: Recruiting
Contact: Huong T. Pham - 800-354-9527
Edwards Comprehensive Cancer Center
Huntington, West Virginia, United States
Status: Recruiting
Contact: Maria R. Tria Tirona - 304-399-6617
Aurora BayCare Medical Center
Green Bay, Wisconsin, United States
Status: Recruiting
Contact: David C. Rohde - 800-252-2990
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, United States
Status: Recruiting
Contact: David C. Rohde - 800-252-2990
Aurora West Allis Medical Center
West Allis, Wisconsin, United States
Status: Recruiting
Contact: David C. Rohde - 800-252-2990
BCCA-Cancer Centre for the Southern Interior
Kelowna, British Columbia, Canada
Status: Active, not recruiting
BCCA-Vancouver Island Cancer Centre
Victoria, British Columbia, Canada
Status: Recruiting
Contact: Caroline L. Holloway - 604-877-6010
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Status: Recruiting
Contact: Iwa Kong - 905-387-9495
London Regional Cancer Program
London, Ontario, Canada
Status: Recruiting
Contact: Brian P. Yaremko - 519-685-8600
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Status: Recruiting
Contact: Evgeny Sadikov - 306-766-2213
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Status: Recruiting
Contact: Vijayananda Kundapur - 306-655-2914
Pamela Youde Nethersole Eastern Hospital
Chai Wan, Hong Kong
Status: Recruiting
Contact: Amy T. Chang - 888-823-5923 - ctsucontact@westat.com
National University Hospital
Singapore, Singapore
Status: Terminated
Start Date
November 2012
Sponsors
Radiation Therapy Oncology Group
Source
Radiation Therapy Oncology Group
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page